Metformin is the first-line antidiabetic therapy for type 2 diabetes in Mexico, despite recent recommendations highlighting alternatives like GLP-1 receptor agonists for individuals with obesity. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.